About: The production of antibodies for SARS-CoV-2 and its clinical implication

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The production of antibodies for SARS-CoV-2 and its clinical implication Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The production of antibodies for SARS-CoV-2 and its clinical implication
Creator	Li, Yan Duan, Jun Wang, Xue Guo, Shuliang Hu, Qianfang Hu, Wenhui Zhu, Linxiao Ao, Zhi Cui, Xiaoping Jiang, Jinyue Liu, Xinzhu Wang, ， Wu, Guicheng
Source	MedRxiv
abstract	Background: Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2), a novel betacoronavirus, has caused an outburst of pneumonia cases in Wuhan, China. We report the production of specific IgM and IgG antibodies after the infection of SARS-CoV-2 and its implication for the diagnosis, pathology and the course of the disease as well as the recurrence of positive nucleic acid tests after discharge. Methods: Test results for SARS-CoV-2 IgM and IgG antibodies of 221 confirmed COVID-19 patients were retrospectively examined, and their clinical data were collected and analyzed based on various subgroups. SARS-CoV-2 IgM and IgG antibodies were determined with the chemiluminescence method. Findings: The concentration (S/CO) of SARS-CoV-2 IgM and IgG antibodies peaked on day 19-21 after symptom onset, with a median of 17.38 (IQR 4.39-36.4) for IgM and 5.59 (IQR 0.73-13.65) for IgG. Detection rates reached highest on day 16-18 and day 19-21 for IgM and IgG, which were 73.6% and 98.6%, respectively, with significantly higher concentration of IgG in critically ill patients than in those with mild to moderate disease (P=0.027). The concentration of the antibodies on day 16-21 is not correlated with the course or outcome of the disease (Spearman r < 0.20, P > 0.05). Nasopharyngeal swabs revealed positive SARS-CoV-2 RNA in up to 52.7% of recovered patients after discharge, whose IgG proved to be significantly lower than that of those with negative RNA results (P = 0.009). IgG and IgM were tested twice within 14 days after discharge with a 7-day interval, and the second testing of these antibodies displayed a decrease in concentration of 21.2% (IQR, 11.2%34.48%) for IgG and 23.05% (IQR, -27.96%46.13%) for IgM, without statistical significance between the patients with re-detectable positive RNA results and those with negative RNA results after discharge. However, those with positive results experienced a count decrease in lymphocyte subsets. Interpretation: The concentration of SARS-CoV-2 IgM and IgG antibodies peaked on day 19-21 after symptom onset, and antibody testing on day 16-21 is associated with increased detection rates, but the antibody concentration does not affect the course and outcome of the infection. Recovering patients with re-detectable positive SARS-CoV-2 RNA displayed lower concentration of IgG, but the downward trend of IgG during recovery indicated its limited duration of protection, and the protective effect of IgG remains to be investigated.
has issue date	2020-04-24(xsd:dateTime)
bibo:doi	10.1101/2020.04.20.20065953
has license	medrxiv
sha1sum (hex)	68c9c407f9ff722f6b28052910f915cad6eeca44
schema:url	https://doi.org/10.1101/2020.04.20.20065953
resource representing a document's title	The production of antibodies for SARS-CoV-2 and its clinical implication
resource representing a document's body	covid:68c9c407f9ff722f6b28052910f915cad6eeca44#body_text
is schema:about of	named entity 'Education' named entity 'EDUCATION' named entity 'antibodies' named entity 'implications' named entity 'FITC' named entity 'IgG' named entity 'radiology' named entity 'symptom' named entity 'IgG antibodies' named entity 'IgM antibodies' named entity 'antibody' named entity 'fever' named entity 'IgG' named entity 'SARS-CoV-2' named entity 'medRxiv' named entity 'SARS-CoV-2' named entity 'IgG' named entity 'nasopharyngeal swabs' named entity 'Chongqing' named entity 'antibodies' named entity 'IgM antibodies' named entity 'RNA' named entity 'standard deviation' named entity 'IgG' named entity 'chemiluminescence' named entity 'nucleic acid' named entity 'CD8' named entity 'medRxiv' named entity 'coronavirus' named entity 'IgM' named entity 'nucleic acid testing' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'interquartile range' named entity 'RT-PCR' named entity 'statistical analysis' named entity 'data acquisition' named entity 'statistically significant' named entity 'early diagnosis' named entity 'fluorescein isothiocyanate' named entity 'antibody tests' named entity 'prognosis' named entity 'early diagnosis' named entity 'nucleic acid' named entity 'epidemic' named entity 'medRxiv' named entity 'immunoassay' named entity 'immune complex' named entity 'pathogen' named entity 'IgG' named entity 'IgG' named entity 'nucleic acid testing' named entity 'epidemic' named entity 'antibody' named entity 'IgG' named entity 'follow-up' named entity 'SARS-CoV-2' named entity 'infection' named entity 'virus' named entity 'antibody testing' named entity 'statistically significant' named entity 'IgM antibodies' named entity 'informed consent' named entity 'peer review' named entity 'IgG' named entity 'IgM' named entity 'China' named entity 'peer review' named entity 'polynomial regression' named entity 'COVID' named entity 'informed consent' named entity 'antibodies' named entity 'study protocol'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software